SCHEDULE: Janus Henderson Boosts Avidity Biosciences Stake

Janus Henderson Group PLC has increased its beneficial ownership in Avidity Biosciences, Inc. to 10.1% of common stock.

Summary

• Janus Henderson Group PLC reported beneficial ownership of 12,132,108 shares of Avidity Biosciences, Inc. common stock.
• This represents 10.1% of Avidity Biosciences' common stock.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.
• Janus Henderson Group PLC, a Jersey-based entity, holds shared voting and dispositive power over these shares.
• Its indirect subsidiary, JHIUS, is deemed the beneficial owner of 11,943,833 shares, representing 9.9% of the class.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual report of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's operational or financial performance. It simply indicates an institutional investor's stake.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in a biotechnology company, which is common for investment firms seeking exposure to growth sectors.

Stakeholder Impact

• This filing primarily impacts shareholders by disclosing a significant institutional stake, which can influence market perception and liquidity.

Key Dates

Keywords

Avidity Biosciences, Janus Henderson, Common Stock, Beneficial Ownership, Schedule 13G, Investment Adviser, Biotechnology, Pharmaceuticals, SEC Filing